Related Experiment Videos
Topiramate. Clinical profile in epilepsy
1Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, New Brunswick, USA.
Clinical Pharmacokinetics
|May 21, 1998
Summary
Topiramate is an effective adjunctive therapy for adult partial-onset seizures, demonstrating consistent seizure reduction with generally mild side effects. Further studies are exploring its use in children and other seizure types.
Area of Science:
- Pharmacology
- Neurology
- Clinical Therapeutics
Background:
- Topiramate is a novel antiepileptic drug (AED) used as adjunctive therapy for adult partial-onset seizures.
- It exhibits favorable pharmacokinetic properties, including rapid absorption, linear kinetics, minimal protein binding, and a long half-life, allowing for twice-daily dosing.
Purpose of the Study:
- To evaluate the efficacy and tolerability of topiramate as adjunctive therapy for partial-onset seizures in adults.
- To explore the potential of topiramate in broader epilepsy populations, including pediatric patients and those with Lennox-Gastaut syndrome or generalized tonic-clonic seizures.
Main Methods:
- Six double-blind, placebo-controlled trials were conducted to assess topiramate's effectiveness and safety.
- Pharmacokinetic interactions with other AEDs, such as phenytoin and carbamazepine, were investigated.
Main Results:
- Topiramate demonstrated consistent seizure reduction across diverse patient groups.
- Adverse effects were predominantly mild-to-moderate central nervous system (CNS) effects, often manageable through dose titration or adjustment of concomitant medications.
- Minimal impact on plasma concentrations of most other AEDs was observed, except for a potential increase in phenytoin levels.
Conclusions:
- Topiramate is a well-tolerated and effective adjunctive treatment for adult partial-onset seizures.
- Preliminary data suggest a broad clinical utility for topiramate in various epilepsy syndromes and age groups.